Cargando…

Low level of Fibrillarin, a ribosome biogenesis factor, is a new independent marker of poor outcome in breast cancer

BACKGROUND: A current critical need remains in the identification of prognostic and predictive markers in early breast cancer. It appears that a distinctive trait of cancer cells is their addiction to hyperactivation of ribosome biogenesis. Thus, ribosome biogenesis might be an innovative source of...

Descripción completa

Detalles Bibliográficos
Autores principales: Nguyen Van Long, Flora, Lardy-Cleaud, Audrey, Carène, Dimitri, Rossoni, Caroline, Catez, Frédéric, Rollet, Paul, Pion, Nathalie, Monchiet, Déborah, Dolbeau, Agathe, Martin, Marjorie, Simioni, Valentin, Bray, Susan, Le Beherec, Doris, Mosele, Fernanda, Bouakka, Ibrahim, Colombe-Vermorel, Amélie, Odeyer, Laetitia, Diot, Alexandra, Jordan, Lee B., Thompson, Alastair M., Jamen, Françoise, Dubois, Thierry, Chabaud, Sylvie, Michiels, Stefan, Treilleux, Isabelle, Bourdon, Jean-Christophe, Pérol, David, Puisieux, Alain, André, Fabrice, Diaz, Jean-Jacques, Marcel, Virginie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9092774/
https://www.ncbi.nlm.nih.gov/pubmed/35545761
http://dx.doi.org/10.1186/s12885-022-09552-x
_version_ 1784705198702198784
author Nguyen Van Long, Flora
Lardy-Cleaud, Audrey
Carène, Dimitri
Rossoni, Caroline
Catez, Frédéric
Rollet, Paul
Pion, Nathalie
Monchiet, Déborah
Dolbeau, Agathe
Martin, Marjorie
Simioni, Valentin
Bray, Susan
Le Beherec, Doris
Mosele, Fernanda
Bouakka, Ibrahim
Colombe-Vermorel, Amélie
Odeyer, Laetitia
Diot, Alexandra
Jordan, Lee B.
Thompson, Alastair M.
Jamen, Françoise
Dubois, Thierry
Chabaud, Sylvie
Michiels, Stefan
Treilleux, Isabelle
Bourdon, Jean-Christophe
Pérol, David
Puisieux, Alain
André, Fabrice
Diaz, Jean-Jacques
Marcel, Virginie
author_facet Nguyen Van Long, Flora
Lardy-Cleaud, Audrey
Carène, Dimitri
Rossoni, Caroline
Catez, Frédéric
Rollet, Paul
Pion, Nathalie
Monchiet, Déborah
Dolbeau, Agathe
Martin, Marjorie
Simioni, Valentin
Bray, Susan
Le Beherec, Doris
Mosele, Fernanda
Bouakka, Ibrahim
Colombe-Vermorel, Amélie
Odeyer, Laetitia
Diot, Alexandra
Jordan, Lee B.
Thompson, Alastair M.
Jamen, Françoise
Dubois, Thierry
Chabaud, Sylvie
Michiels, Stefan
Treilleux, Isabelle
Bourdon, Jean-Christophe
Pérol, David
Puisieux, Alain
André, Fabrice
Diaz, Jean-Jacques
Marcel, Virginie
author_sort Nguyen Van Long, Flora
collection PubMed
description BACKGROUND: A current critical need remains in the identification of prognostic and predictive markers in early breast cancer. It appears that a distinctive trait of cancer cells is their addiction to hyperactivation of ribosome biogenesis. Thus, ribosome biogenesis might be an innovative source of biomarkers that remains to be evaluated. METHODS: Here, fibrillarin (FBL) was used as a surrogate marker of ribosome biogenesis due to its essential role in the early steps of ribosome biogenesis and its association with poor prognosis in breast cancer when overexpressed. Using 3,275 non-metastatic primary breast tumors, we analysed FBL mRNA expression levels and protein nucleolar organisation. Usage of TCGA dataset allowed transcriptomic comparison between the different FBL expression levels-related breast tumours. RESULTS: We unexpectedly discovered that in addition to breast tumours expressing high level of FBL, about 10% of the breast tumors express low level of FBL. A correlation between low FBL mRNA level and lack of FBL detection at protein level using immunohistochemistry was observed. Interestingly, multivariate analyses revealed that these low FBL tumors displayed poor outcome compared to current clinical gold standards. Transcriptomic data revealed that FBL expression is proportionally associated with distinct amount of ribosomes, low FBL level being associated with low amount of ribosomes. Moreover, the molecular programs supported by low and high FBL expressing tumors were distinct. CONCLUSION: Altogether, we identified FBL as a powerful ribosome biogenesis-related independent marker of breast cancer outcome. Surprisingly we unveil a dual association of the ribosome biogenesis FBL factor with prognosis. These data suggest that hyper- but also hypo-activation of ribosome biogenesis are molecular traits of distinct tumors. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12885-022-09552-x.
format Online
Article
Text
id pubmed-9092774
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-90927742022-05-12 Low level of Fibrillarin, a ribosome biogenesis factor, is a new independent marker of poor outcome in breast cancer Nguyen Van Long, Flora Lardy-Cleaud, Audrey Carène, Dimitri Rossoni, Caroline Catez, Frédéric Rollet, Paul Pion, Nathalie Monchiet, Déborah Dolbeau, Agathe Martin, Marjorie Simioni, Valentin Bray, Susan Le Beherec, Doris Mosele, Fernanda Bouakka, Ibrahim Colombe-Vermorel, Amélie Odeyer, Laetitia Diot, Alexandra Jordan, Lee B. Thompson, Alastair M. Jamen, Françoise Dubois, Thierry Chabaud, Sylvie Michiels, Stefan Treilleux, Isabelle Bourdon, Jean-Christophe Pérol, David Puisieux, Alain André, Fabrice Diaz, Jean-Jacques Marcel, Virginie BMC Cancer Research BACKGROUND: A current critical need remains in the identification of prognostic and predictive markers in early breast cancer. It appears that a distinctive trait of cancer cells is their addiction to hyperactivation of ribosome biogenesis. Thus, ribosome biogenesis might be an innovative source of biomarkers that remains to be evaluated. METHODS: Here, fibrillarin (FBL) was used as a surrogate marker of ribosome biogenesis due to its essential role in the early steps of ribosome biogenesis and its association with poor prognosis in breast cancer when overexpressed. Using 3,275 non-metastatic primary breast tumors, we analysed FBL mRNA expression levels and protein nucleolar organisation. Usage of TCGA dataset allowed transcriptomic comparison between the different FBL expression levels-related breast tumours. RESULTS: We unexpectedly discovered that in addition to breast tumours expressing high level of FBL, about 10% of the breast tumors express low level of FBL. A correlation between low FBL mRNA level and lack of FBL detection at protein level using immunohistochemistry was observed. Interestingly, multivariate analyses revealed that these low FBL tumors displayed poor outcome compared to current clinical gold standards. Transcriptomic data revealed that FBL expression is proportionally associated with distinct amount of ribosomes, low FBL level being associated with low amount of ribosomes. Moreover, the molecular programs supported by low and high FBL expressing tumors were distinct. CONCLUSION: Altogether, we identified FBL as a powerful ribosome biogenesis-related independent marker of breast cancer outcome. Surprisingly we unveil a dual association of the ribosome biogenesis FBL factor with prognosis. These data suggest that hyper- but also hypo-activation of ribosome biogenesis are molecular traits of distinct tumors. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12885-022-09552-x. BioMed Central 2022-05-11 /pmc/articles/PMC9092774/ /pubmed/35545761 http://dx.doi.org/10.1186/s12885-022-09552-x Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Nguyen Van Long, Flora
Lardy-Cleaud, Audrey
Carène, Dimitri
Rossoni, Caroline
Catez, Frédéric
Rollet, Paul
Pion, Nathalie
Monchiet, Déborah
Dolbeau, Agathe
Martin, Marjorie
Simioni, Valentin
Bray, Susan
Le Beherec, Doris
Mosele, Fernanda
Bouakka, Ibrahim
Colombe-Vermorel, Amélie
Odeyer, Laetitia
Diot, Alexandra
Jordan, Lee B.
Thompson, Alastair M.
Jamen, Françoise
Dubois, Thierry
Chabaud, Sylvie
Michiels, Stefan
Treilleux, Isabelle
Bourdon, Jean-Christophe
Pérol, David
Puisieux, Alain
André, Fabrice
Diaz, Jean-Jacques
Marcel, Virginie
Low level of Fibrillarin, a ribosome biogenesis factor, is a new independent marker of poor outcome in breast cancer
title Low level of Fibrillarin, a ribosome biogenesis factor, is a new independent marker of poor outcome in breast cancer
title_full Low level of Fibrillarin, a ribosome biogenesis factor, is a new independent marker of poor outcome in breast cancer
title_fullStr Low level of Fibrillarin, a ribosome biogenesis factor, is a new independent marker of poor outcome in breast cancer
title_full_unstemmed Low level of Fibrillarin, a ribosome biogenesis factor, is a new independent marker of poor outcome in breast cancer
title_short Low level of Fibrillarin, a ribosome biogenesis factor, is a new independent marker of poor outcome in breast cancer
title_sort low level of fibrillarin, a ribosome biogenesis factor, is a new independent marker of poor outcome in breast cancer
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9092774/
https://www.ncbi.nlm.nih.gov/pubmed/35545761
http://dx.doi.org/10.1186/s12885-022-09552-x
work_keys_str_mv AT nguyenvanlongflora lowleveloffibrillarinaribosomebiogenesisfactorisanewindependentmarkerofpooroutcomeinbreastcancer
AT lardycleaudaudrey lowleveloffibrillarinaribosomebiogenesisfactorisanewindependentmarkerofpooroutcomeinbreastcancer
AT carenedimitri lowleveloffibrillarinaribosomebiogenesisfactorisanewindependentmarkerofpooroutcomeinbreastcancer
AT rossonicaroline lowleveloffibrillarinaribosomebiogenesisfactorisanewindependentmarkerofpooroutcomeinbreastcancer
AT catezfrederic lowleveloffibrillarinaribosomebiogenesisfactorisanewindependentmarkerofpooroutcomeinbreastcancer
AT rolletpaul lowleveloffibrillarinaribosomebiogenesisfactorisanewindependentmarkerofpooroutcomeinbreastcancer
AT pionnathalie lowleveloffibrillarinaribosomebiogenesisfactorisanewindependentmarkerofpooroutcomeinbreastcancer
AT monchietdeborah lowleveloffibrillarinaribosomebiogenesisfactorisanewindependentmarkerofpooroutcomeinbreastcancer
AT dolbeauagathe lowleveloffibrillarinaribosomebiogenesisfactorisanewindependentmarkerofpooroutcomeinbreastcancer
AT martinmarjorie lowleveloffibrillarinaribosomebiogenesisfactorisanewindependentmarkerofpooroutcomeinbreastcancer
AT simionivalentin lowleveloffibrillarinaribosomebiogenesisfactorisanewindependentmarkerofpooroutcomeinbreastcancer
AT braysusan lowleveloffibrillarinaribosomebiogenesisfactorisanewindependentmarkerofpooroutcomeinbreastcancer
AT lebeherecdoris lowleveloffibrillarinaribosomebiogenesisfactorisanewindependentmarkerofpooroutcomeinbreastcancer
AT moselefernanda lowleveloffibrillarinaribosomebiogenesisfactorisanewindependentmarkerofpooroutcomeinbreastcancer
AT bouakkaibrahim lowleveloffibrillarinaribosomebiogenesisfactorisanewindependentmarkerofpooroutcomeinbreastcancer
AT colombevermorelamelie lowleveloffibrillarinaribosomebiogenesisfactorisanewindependentmarkerofpooroutcomeinbreastcancer
AT odeyerlaetitia lowleveloffibrillarinaribosomebiogenesisfactorisanewindependentmarkerofpooroutcomeinbreastcancer
AT diotalexandra lowleveloffibrillarinaribosomebiogenesisfactorisanewindependentmarkerofpooroutcomeinbreastcancer
AT jordanleeb lowleveloffibrillarinaribosomebiogenesisfactorisanewindependentmarkerofpooroutcomeinbreastcancer
AT thompsonalastairm lowleveloffibrillarinaribosomebiogenesisfactorisanewindependentmarkerofpooroutcomeinbreastcancer
AT jamenfrancoise lowleveloffibrillarinaribosomebiogenesisfactorisanewindependentmarkerofpooroutcomeinbreastcancer
AT duboisthierry lowleveloffibrillarinaribosomebiogenesisfactorisanewindependentmarkerofpooroutcomeinbreastcancer
AT chabaudsylvie lowleveloffibrillarinaribosomebiogenesisfactorisanewindependentmarkerofpooroutcomeinbreastcancer
AT michielsstefan lowleveloffibrillarinaribosomebiogenesisfactorisanewindependentmarkerofpooroutcomeinbreastcancer
AT treilleuxisabelle lowleveloffibrillarinaribosomebiogenesisfactorisanewindependentmarkerofpooroutcomeinbreastcancer
AT bourdonjeanchristophe lowleveloffibrillarinaribosomebiogenesisfactorisanewindependentmarkerofpooroutcomeinbreastcancer
AT peroldavid lowleveloffibrillarinaribosomebiogenesisfactorisanewindependentmarkerofpooroutcomeinbreastcancer
AT puisieuxalain lowleveloffibrillarinaribosomebiogenesisfactorisanewindependentmarkerofpooroutcomeinbreastcancer
AT andrefabrice lowleveloffibrillarinaribosomebiogenesisfactorisanewindependentmarkerofpooroutcomeinbreastcancer
AT diazjeanjacques lowleveloffibrillarinaribosomebiogenesisfactorisanewindependentmarkerofpooroutcomeinbreastcancer
AT marcelvirginie lowleveloffibrillarinaribosomebiogenesisfactorisanewindependentmarkerofpooroutcomeinbreastcancer